Back to News​
Press Release

Alamar Biosciences and Biomarkers of Aging Consortium Join Forces to Revolutionize Longevity Research

Back to Publications​
  • June 27, 2024

Fremont, CA – Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease in collaboration with the Biomarkers of Aging Consortium, a consortium dedicated to the development and validation of biomarkers of aging and longevity, announced today the launch of the next phase of the Biomarkers of Aging Challenge Series. This initiative aims to address one of the most significant challenges in the longevity field: the need for reliable biomarkers of biological age.

“The Challenge Series aims to drive innovation in the aging biomarkers space and bring new scientists into this research arena,” said Dr. Jesse Poganik of the Biomarkers of Aging Consortium. “Our hope is that challenge participants leveraging the latest omics profiling methods and novel modeling approaches will produce the next generation of aging biomarkers.”

The Biomarkers of Aging Challenge is supported by a unique, high-quality dataset specifically generated for this initiative. This dataset includes proteomic profiles using the NULISAseq™ Inflammation 250 and CNS Disease 120 Panels, DNA methylation profiles, and aging outcome data from over 500 diverse individuals.  Importantly, it includes longitudinal follow-up data, enabling the modeling of mortality risk, future disease incidence, and multi-morbidity occurrence.

“The partnership between Alamar Biosciences and the Biomarkers of Aging Consortium underscores a shared commitment to driving innovation and collaboration in the field of aging biomarkers,” said Dr. Yuling Luo, Founder, Chairman & CEO of Alamar. “By leveraging Alamar’s high-sensitivity proteomics technologies and the Consortium’s extensive expertise and resources, the Challenge seeks to accelerate progress in this critical area.”

Submissions to the Challenge will not only contribute to identifying current predictive biomarkers but also support continuous technology development, paving the way for future cost-effective technological advancements for longitudinal and large-scale studies.

Challenge Timeline:

  • March 1, 2024: Phase I – Chronological Age Prediction Challenge begins
  • July 1, 2024: Phase II – Longevity Prediction Challenge (Mortality) begins
  • November 1, 2024: Winners celebration at the 2024 Biomarkers of Aging Conference in Boston, MA
  • Q1 2025: Phase III – Healthspan Prediction (Multi-morbidity) begins

For more information about the Biomarkers of Aging Challenge Series, please visit https://www.agingconsortium.org/challenge

About Alamar Biosciences, Inc.

Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company’s proprietary NULISA Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com.

About the Biomarkers of Aging Consortium

Founded in 2022, the Biomarkers of Aging Consortium is a group of scholars and practitioners developing, validating, and implementing biomarkers of aging and longevity. Our academic members are affiliated with the leading research institutes and groups in the field of aging. Our practitioners are at the forefront of research and development in the longevity industry. www.agingconsortium.org

Linkedin

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Linkedin

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition.  He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.